These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Drugs used in heart disease. 3. Applications. Shulman R; Davies R; Landowski R Nurs Times; 2002 May 14-20; 98(20):43-6. PubMed ID: 12168400 [No Abstract] [Full Text] [Related]
6. Three Generations of β-blockers: History, Class Differences and Clinical Applicability. do Vale GT; Ceron CS; Gonzaga NA; Simplicio JA; Padovan JC Curr Hypertens Rev; 2019; 15(1):22-31. PubMed ID: 30227820 [TBL] [Abstract][Full Text] [Related]
7. Beta blockers as cardioprotective agents: Part I--Insights into mechanisms of action. Frishman WH Am J Manag Care; 2002 Jun; 8(9 Suppl):13-7. PubMed ID: 12099323 [No Abstract] [Full Text] [Related]
8. Carvedilol induces biased β1 adrenergic receptor-nitric oxide synthase 3-cyclic guanylyl monophosphate signalling to promote cardiac contractility. Wang Q; Wang Y; West TM; Liu Y; Reddy GR; Barbagallo F; Xu B; Shi Q; Deng B; Wei W; Xiang YK Cardiovasc Res; 2021 Aug; 117(10):2237-2251. PubMed ID: 32956449 [TBL] [Abstract][Full Text] [Related]
9. Beta-blocker-induced heart rate lowering, cardioprotection, and hypertension. Khan SS J Am Coll Cardiol; 2009 Jun; 53(22):2104-5; author reply 2106-7. PubMed ID: 19477368 [No Abstract] [Full Text] [Related]
10. Cardioprotective effects of the Ιf current inhibition by ivabradine during cardiac dysfunction. Su JB Curr Pharm Biotechnol; 2014; 14(14):1213-9. PubMed ID: 24831809 [TBL] [Abstract][Full Text] [Related]
11. Β-blockers treatment of cardiac surgery patients enhances isolation and improves phenotype of cardiosphere-derived cells. Chimenti I; Pagano F; Cavarretta E; Angelini F; Peruzzi M; Barretta A; Greco E; De Falco E; Marullo AG; Sciarretta S; Biondi-Zoccai G; Frati G Sci Rep; 2016 Nov; 6():36774. PubMed ID: 27841293 [TBL] [Abstract][Full Text] [Related]
12. Pycnogenol increases the probability of the contraction state in chick embryonic cardiomyocytes, indicating inotropic effects. Hasegawa N; Kinoshita H; Mochizuki M Phytother Res; 2007 Feb; 21(2):181-2. PubMed ID: 17078108 [TBL] [Abstract][Full Text] [Related]
13. Cardioprotection: the role of beta-blocker therapy. Egan BM; Basile J; Chilton RJ; Cohen JD J Clin Hypertens (Greenwich); 2005 Jul; 7(7):409-16. PubMed ID: 16015051 [TBL] [Abstract][Full Text] [Related]
14. Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure. Berger R; Moertl D; Huelsmann M; Bojic A; Ahmadi R; Heissenberger I; Pacher R Eur J Heart Fail; 2007 Feb; 9(2):202-8. PubMed ID: 16859992 [TBL] [Abstract][Full Text] [Related]
15. Cardioprotective and survival benefits of long-term combined therapy with beta2 adrenoreceptor (AR) agonist and beta1 AR blocker in dilated cardiomyopathy postmyocardial infarction. Ahmet I; Krawczyk M; Zhu W; Woo AY; Morrell C; Poosala S; Xiao RP; Lakatta EG; Talan MI J Pharmacol Exp Ther; 2008 May; 325(2):491-9. PubMed ID: 18287209 [TBL] [Abstract][Full Text] [Related]
19. Anthracycline-associated cardiotoxicity in adults: systematic review on the cardioprotective role of beta-blockers. Barbosa RR; Bourguignon TB; Torres LD; Arruda LS; Jacques TM; Serpa RG; Calil OA; Barbosa LFM Rev Assoc Med Bras (1992); 2018 Aug; 64(8):745-754. PubMed ID: 30673046 [TBL] [Abstract][Full Text] [Related]
20. Molecular, Cellular, and Clinical Evidence That Sodium-Glucose Cotransporter 2 Inhibitors Act as Neurohormonal Antagonists When Used for the Treatment of Chronic Heart Failure. Packer M J Am Heart Assoc; 2020 Aug; 9(16):e016270. PubMed ID: 32791029 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]